ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

volrustomig

Also written as “Volrustomig”, “MEDI5752” and “AZD9592 + Volrustomig”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Uterine Cervical Neoplasms · Squamous Cell Carcinoma of Head and Neck · Stomach Neoplasms · Carcinoma, Renal Cell, led by 2 companies.

Drug pageVolrustomig: every studyAll 23 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Aug 2, 202319 company-led studies, 17 open or runningNext primary completion: Jan 29, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca1716 open or runningphase 3since Aug 2, 2023Mar 28, 2018Jan 29, 2027phase 1 · NCT07000149
Presage Biosciencesits history only21 open or runningearly phase 1since Sep 1, 2020Sep 1, 2020Dec 2031early phase 1 · NCT04541108
  • Named in AstraZeneca’s own pipeline as volrustomig, phase 3, as of Oct 30, 2026 (source).

Also a collaborator on its studies: Parexel, Daiichi Sankyo and Arcus Biosciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AstraZeneca only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Mar 28, 2018.

  1. Jul 22, 2020Phase 1 study in Carcinoma, Renal CellNCT04522323 · 67 enrolled · United States, Australia, France and more
  2. Sep 20, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05061550 · 630 planned · United States, Belgium, Canada and more
  3. Jul 21, 2022Named volrustomigINNProposed as its International Nonproprietary Name in WHO's List 127 · before, MEDI5752
  4. Nov 9, 2022Phase 1 study in Advanced Solid TumorsNCT05685472 · 6 enrolled · Japan
  5. Dec 7, 2022Phase 2 study in Stomach NeoplasmsNCT05702229 · 163 planned · United States, China, Japan and more
  6. Mar 2, 2023Phase 2 study in Carcinoma, HepatocellularNCT05775159 · 294 enrolled · United States, China, Hong Kong and more
  7. Aug 2, 2023Phase 3 study in Carcinoma, Non-Small-Cell LungNCT05984277 · 895 enrolled · United States, Argentina, Australia and more
  8. Sep 4, 2023Phase 3 study in Locally Advanced Cervical CancerNCT06079671 · 800 planned · United States, Brazil, Canada and more
  9. Oct 4, 2023Phase 3 study in MesotheliomaNCT06097728 · 863 enrolled · United States, Australia, Belgium and more
  10. Nov 3, 2023Phase 3 study in Locally Advanced Head and Neck Squamous Cell CarcinomaNCT06129864 · 1,145 planned · United States, Austria, Belgium and more
  11. Jun 4, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06448754 · 194 enrolled · United States, China, France and more
  12. Jul 31, 2024Phase 2 study in Uterine Cervical NeoplasmsNCT06535607 · 257 planned · United States, Australia, Brazil and more
  13. Jan 20, 2025Phase 2 study in Colorectal NeoplasmsNCT06792695 · 82 enrolled · United States, Australia, Canada and more
  14. Mar 11, 2025Phase 2 study in Locally Advanced Cervical CancerNCT06943833 · 37 enrolled · Russia
  15. May 23, 2025Phase 1 study in Diabetes Mellitus, Insulin-Dependent, 12NCT07000149 · 9 enrolled · Australia, South Korea

Ahead

  1. Jan 29, 2027Primary completion: phase 1 study in Diabetes Mellitus, Insulin-Dependent, 12NCT07000149
  2. May 4, 2027Primary completion: phase 2 study in Stomach NeoplasmsNCT04379596
  3. Jun 30, 2027Primary completion: phase 2 study in Colorectal NeoplasmsNCT06792695
  4. Jul 30, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT06448754

TargetBeta

“An engineered fragment crystallizable (Fc) domain bispecific human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CT…”NCIt, read by Claude
“An engineered fragment crystallizable (Fc) domain bispecific human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
cadonilimabruleAkesophase 345
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
lorigerlimabruleMacroGenicsphase 24
Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rulehc-biopharma-incphase 22

Studies

All 17 AstraZeneca leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07000149Diabetes Mellitus, Insulin-Dependent, 12 · Australia, South Korea1Active, not recruitingJan 29, 20279
NCT06943833Locally Advanced Cervical Cancer · Russia2Active, not recruitingMar 13, 202837
NCT06792695Colorectal Neoplasms · United States, Australia, Canada and more2Active, not recruitingJun 30, 202782
NCT06535607Uterine Cervical Neoplasms · United States, Australia, Brazil and more2RecruitingNov 30, 2028257
NCT06448754Carcinoma, Non-Small-Cell Lung · United States, China, France and more2Active, not recruitingJul 30, 2027194
NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma · United States, Austria, Belgium and more3RecruitingApr 17, 20301,145
NCT06097728Mesothelioma · United States, Australia, Belgium and more3Active, not recruitingNov 16, 2028863
NCT06079671Locally Advanced Cervical Cancer · United States, Brazil, Canada and more3RecruitingNov 26, 2027800
NCT05984277Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3Active, not recruitingAug 17, 2026895
NCT05775159Carcinoma, Hepatocellular · United States, China, Hong Kong and more2Active, not recruitingOct 27, 2026294
NCT05702229Stomach Neoplasms · United States, China, Japan and more2RecruitingNov 30, 2027163
NCT05685472Advanced Solid Tumors · Japan1CompletedAug 8, 20236
NCT05061550Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more2RecruitingMay 28, 2030630
NCT04522323Carcinoma, Renal Cell · United States, Australia, France and more1Active, not recruitingSep 26, 202567
NCT04379596Stomach Neoplasms · United States, Brazil, Canada and more2Active, not recruitingMay 4, 2027452
NCT03819465Carcinoma, Non-Small-Cell Lung · United States, Austria, Belgium and more1Active, not recruitingMay 23, 2023175
NCT03530397Neoplasms · United States, Australia, France and more1Active, not recruitingJul 14, 2025400

How it is read

Names in the registry

  • “Volrustomig”, 14 entries
  • “MEDI5752”, 4 entries
  • “AZD9592 + Volrustomig”, 2 entries
  • “volrustomig”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.